Clinical Trials Logo

CLL Progression clinical trials

View clinical trials related to CLL Progression.

Filter by:
  • None
  • Page 1

NCT ID: NCT04811950 Not yet recruiting - CLL Progression Clinical Trials

Prognostic Role of Platelet _lymphocyte and Neutrophil _monocyte in CLL

Start date: June 2022
Phase:
Study type: Observational

The biological rationale in calculating PLR stems from the increase in the lymphocyte count and reduction in the platelet count often encountered in the advances stages of CLL .NMR median value was significantly higher in untreated patients than in patients who received treatment strengthening the hypothesis that this ratio is associated with a more indolent form of disease

NCT ID: NCT04149821 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Start date: February 10, 2021
Phase: Phase 2
Study type: Interventional

This study evaluates the efficacy and safety of umbralisib and ublituximab (U2) as salvage therapy in patients with chronic lymphocytic leukemia (CLL) who have progressed either on a BTK inhibitor (BTKi) or BCL-2 inhibitor. The study will evaluate this combination in two parallel cohorts and subjects will be assigned based on which class of novel agent-containing regimen was used prior. Cohort A will consist of patients who progress after BTKi containing regimens and Cohort B will consist of patients who progress after a BCL-2 containing regimen. Subjects who progress on a regimen containing both a BTKi and a BCL-2 inhibitor, will be enrolled in cohort B. Each cohort will be evaluated independently of each other.